Menu
GeneBe

CDK2AP1

cyclin dependent kinase 2 associated protein 1

Basic information

Region (hg38): 12:123250111-123272334

Links

ENSG00000111328NCBI:8099OMIM:602198HGNC:14002Uniprot:O14519AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CDK2AP1 gene.

  • Combined oxidative phosphorylation defect type 7;Spastic paraplegia (53 variants)
  • not provided (42 variants)
  • Combined oxidative phosphorylation defect type 7 (41 variants)
  • Spastic paraplegia;Combined oxidative phosphorylation defect type 7 (29 variants)
  • Hereditary spastic paraplegia (11 variants)
  • not specified (8 variants)
  • Hereditary spastic paraplegia 55 (6 variants)
  • Combined oxidative phosphorylation deficiency (4 variants)
  • Inborn genetic diseases (3 variants)
  • Hereditary spastic paraplegia 55;Combined oxidative phosphorylation defect type 7 (1 variants)
  • MTRFR-related condition (1 variants)
  • Epileptic encephalopathy (1 variants)
  • Abnormal brain morphology (1 variants)
  • Neurodevelopmental disorder (1 variants)
  • Combined oxidative phosphorylation defect type 7;Hereditary spastic paraplegia 55 (1 variants)
  • Hereditary motor and sensory neuropathy with optic atrophy (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CDK2AP1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
2
missense
3
clinvar
3
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
1
1
non coding
8
clinvar
9
clinvar
78
clinvar
30
clinvar
8
clinvar
133
Total 8 9 81 30 10

Highest pathogenic variant AF is 0.000118

Variants in CDK2AP1

This is a list of pathogenic ClinVar variants found in the CDK2AP1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
12-123252157-GATGCAGTGGCTCACGCCTGTAATCCCAGAACTTTGGGAGGCTGAAGCAGGTGGATTACTTGACCTTAGGGAGTTCAAGACCAGCCTGGGCAATATGGCGAAACCCCATCTCTACAAAAAGTAATTACTCAGATGTGGTGGTGTCTGCCTGTAGTCTTCACCTACTAGGGAGCCTGAGGTGACAGAATCGCCTGACCCTGGGGAAGTCAAGGCTGCAGTGAGCTGTGATCGCGCCACTGCAGTCCAGCCTGGGCGACAGAGTGGGACTCTGTCTCAAAAAAAAAAAAAAAATTAGTTGACTTGGTAGTTCCAACGATGAGTACCAGTTGGACCACGTTGTTGGCAGTGCGTCCAGGGAACAGATGTTCACATTCAAATCCATGAAACTGGAAACAAAAAACAACAATCATGACATTGATTGATAGTGATGTTTACTATGTCAGACTGTTTAAGCTCAGCTATAAAATAGACTACTCAGCCCTGGGTGGGGGTGGGGGGTGGCTCACACTTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACCTGAGGTCAGGAATTCGAGACCAGCCTGGCCAACATGGTGAATCCCCGCCTCTACTAAAAATACAAAAATTAGCCGGGTGTGGTGGCACACGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCCAAGATCGCGCCATCGCACTCCAGCCTGGGCGACAGAGCGAGATTCCGTCTCAAAAAATAAAATAGACTCTCATACTGTCATCTTTACATTTTGATTTCAGAGATTCTCAAACATTTAAATACTGGCACTTGACCCAGATCCTAATTTTTGCTTGATGCACTATTTACCTGTATCAAATTACAGTCCGTTCCTTTGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGACACTGTCTCGCTCTGTTGTCCAGGCTGGAGTGCAGTGGCTCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCACCCACCACCAAGCCCGGCTAATTTTTGTATTTTTAGTAGAGATAGTTTCATCATCTTGGCCAGGCTGGTCTTGAACTCCTGACCTTGTGATCCACCTGCCTCGGCCTCCCAAAGTGCTTGGATTACAGGTGTGAGCCACCATGCCCGGCCTGAATTTCACACTCAAAACCTCTCCTTTCTGAGAAAACAGCACCCCCGGGTGCTTGGAAGATATTTTTGGTCTATTGCAAGAAAATATGTATTAGCTGGCAGGGCATGTCCTGGTAACATGGCAGACAGTGCAAGGCTGAGGAGAGGGGCGTCTTGCTGAATAATGTGTCTCTACTCATTTCCTAAATTCCCTCGGTAACAGATGGGTCATCATTTGAATTGCTTTATAAAAAGCTGTCTTTGAATCTGAAGCATAATCTTGAGGGCAGATGCCTCTTACTGAAAGCTCTCCTTATTCATCTAACCCAGGTCCTCAGCCAGCAGAGCCACGTTCCTTATGAGCACCGTGGGTTTATTTCATTTTCCTACACCACTGACCCGAATATGCCCGGCGCCATGGGGACTCCGGCTTTGGGAGAAGCTGACGTTGTTATCCCCAGGAATAGCTGTCACTCCGGTCCAGATGGCAGGCAAGAAGGACTACCCTGCACTGCTTTCCTTGGATGAGAATGAACTCGAAGAGCAGTTTGTGAAAGGACACGGTCCAGGGGGCCAGGCAACCAACAAAACCAGCAACTGCGTGGTGCTGAAGCACATCCCCTCAGGCATCGTTGTAAAGGTAGATCACAGAAGGCCGCTGAGGGGAGAGGCCCCGCCCAAGGGTTCCACAGCCTCCAGAGATTTCTCCCAAGTGTGAATGGGATCAGCCGAAGTGCATTATTTTTCTGGCTTGGGCCACCCTCTACCAGCCAGGCAGTAGAGAGCACCGCAGATCTCGTCCCATCCCTGAGCCATTCCTCCCTAAGGCAGAACCTCCTACAACAGCCTGGGAAGCCTGTTTCCAGGATCTTTTGGAGCCAGGGTATGGCTGCCATCCTTGAATTTGGCAGACAGCACTGGTGCTTGGCTGCTGCCCCGGAAGCAACGTCTTGACAAAGCTAAGCAGTGGCTGATAAAGGCAGGCGCCCGGGCAGCATGGTTCTTTCAAATCCGTTCCCACTGCAGGAAGGCTGCCGAGATCCCCAGCATTGCTATGGGATCCAAGTCCCTGAGGAGGCGGCAAGCAGGCATGGGTTGTCTGCTGGCAGTCCCAGCCCTTAACTGTCATGGCTGGTTAACATTAGGGTGGCCACATCCTCCACGCCTCTCTGTCCCCTTTGGTAAATGTCGGTGATACCTCCTCTTCTGGACAGAGAGGACTGAGGGCGAGATCATGGAGGATCATGGAGGCCAGGCATTTTCCAACCTCAGAAGAAAAAATGCTGTGCACAGCTGCCTATAGGAGTCTTCCTTTTTACATAAAAAAACAAGTCTCGGGCCAGGCACAGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATCACCTGAGGTCAGGAGTTCGAGACCAGTCTGGTCAACATGGCAAAACCCCATCTCTACTGAAAATACAAAAATTAGCCGGGTGTGGTGGCGCGTGCCTGTAATCCCAGTTACTCGGAGGCTAAGGCAGGAGAATCGCTTGAACCCTGGAGGCAGACATTGCAGTGAGCCGAGATCATGCTACTGCATACCAGCCTGGGCAACAGACAAGATTCCCTCTTAAAAAAAAAAAAAAGAAGGTTGGTCAGAGGGGCTCCCAGTCCATCTGCCTCAGGGATCACGAGAGAGTCCTGGAAGCAGCACAGAAGAGAGATAGCCAAGGCAGGTGTTTCATATATAACGATACTGGCAGCAGATACTTACAGGTCATGGAAACGTGTGGGAGGAACTGTTCGAAGCAGCATTAACTCTGCAGTCCCCAAAACCCCATGTTCATGATTTCCATCACAGTACAGGTGTGGAATCTGGGACATAGAGAGGCTAAGTGACCTGCCCAAGGTCCTGCCACTCAGTAGTCAGTTCACACCATACCCCAAGTCCATGTTCCTAACAGCTGCACTTCACTGCTGGGTTTCTGAGCCACAAGCATATCATGTAAAACCTCAATCATTTCTTTTCCCCCTTGAAAAGTGTCATTCATGAGTAACAAAATTCTGAAACCTGAGAGTTAATTTTTGTTTAACCTATTTGACATAACTCAATCCAAACTTGCTTTCAGAATTATTCTTTAACCCTAATTTCATAGAATTTTTTTTTTTTTAAGAGACAGGGTCTTGTTTTGTCAGCCAGGTTGGAGTGCAGTGGTGCAATCATGGCTCAGTATAGCCTCAAACACCTGGGCTCAAGCAATCCTCCCGCCTCGGCCTCCCGAGTAGCTGGGACTGCAGGCATGCCCCACCACACTCAGTGTTTTTTGTTTCGTTTTGTTTTTTGAGACAGTCTTGCTCTATTGCCCAGGCTGGAGTGCAGTGGCGCAATCTCAGCTCACTGCAACGTCCGCCTCCTGGGTTCAAGCAATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGTGCCCATCACCACGCCCAGCTAATTTTTTTGTATTTTTACTAGAGACAAGGTTTCACCATGTTGGCCAGGCTGGTTT-G Neurodevelopmental disorder Pathogenic (Apr 09, 2019)635867
12-123253386-G-T Benign (Jun 14, 2018)680559
12-123253667-C-T MTRFR-related disorder Likely benign (May 28, 2019)3038885
12-123253683-C-T Combined oxidative phosphorylation defect type 7;Spastic paraplegia Likely benign (Mar 09, 2022)2419174
12-123253688-GTTTA-G Hereditary motor and sensory neuropathy with optic atrophy Likely pathogenic (Dec 01, 2020)1048600
12-123253696-C-G Combined oxidative phosphorylation defect type 7;Spastic paraplegia Uncertain significance (Aug 10, 2022)1929241
12-123253700-T-C Spastic paraplegia;Combined oxidative phosphorylation defect type 7 Uncertain significance (Apr 27, 2023)2067895
12-123253706-C-T Combined oxidative phosphorylation defect type 7;Spastic paraplegia Uncertain significance (Aug 16, 2021)1681651
12-123253706-C-CA Combined oxidative phosphorylation defect type 7;Spastic paraplegia Pathogenic (Feb 05, 2019)859045
12-123253708-C-T Combined oxidative phosphorylation defect type 7 • Combined oxidative phosphorylation defect type 7;Spastic paraplegia Uncertain significance (Jan 09, 2023)307494
12-123253715-C-T Combined oxidative phosphorylation defect type 7;Spastic paraplegia Uncertain significance (Aug 04, 2023)2037642
12-123253717-C-T Likely pathogenic (Dec 18, 2022)1323989
12-123253718-G-A not specified • Combined oxidative phosphorylation defect type 7;Spastic paraplegia • Combined oxidative phosphorylation defect type 7 • Hereditary spastic paraplegia Benign (Jan 31, 2024)128535
12-123253721-T-C Uncertain significance (Jul 28, 2022)2412984
12-123253727-C-T Combined oxidative phosphorylation defect type 7;Spastic paraplegia Uncertain significance (May 06, 2022)502352
12-123253728-G-A Combined oxidative phosphorylation defect type 7;Spastic paraplegia • Hereditary spastic paraplegia Conflicting classifications of pathogenicity (Jan 17, 2024)697230
12-123253730-C-T Combined oxidative phosphorylation defect type 7 • Combined oxidative phosphorylation defect type 7;Spastic paraplegia Uncertain significance (Aug 19, 2022)307495
12-123253731-G-A Combined oxidative phosphorylation defect type 7;Spastic paraplegia Likely benign (Nov 27, 2018)700950
12-123253745-G-A Combined oxidative phosphorylation defect type 7;Spastic paraplegia Uncertain significance (Oct 17, 2022)1212115
12-123253745-G-T Spastic paraplegia;Combined oxidative phosphorylation defect type 7 Uncertain significance (Mar 11, 2022)1309118
12-123253764-G-A Combined oxidative phosphorylation defect type 7 • Spastic paraplegia;Combined oxidative phosphorylation defect type 7 Conflicting classifications of pathogenicity (Jan 30, 2023)307496
12-123253767-G-A Combined oxidative phosphorylation defect type 7;Spastic paraplegia Likely benign (Oct 05, 2023)2938984
12-123253769-T-TATCC Spastic paraplegia;Combined oxidative phosphorylation defect type 7 • Hereditary spastic paraplegia 55;Combined oxidative phosphorylation defect type 7 Pathogenic (Dec 17, 2023)214192
12-123253773-C-T Combined oxidative phosphorylation defect type 7;Spastic paraplegia Likely benign (Jul 31, 2019)1158561
12-123253778-GA-AT Combined oxidative phosphorylation defect type 7;Spastic paraplegia Uncertain significance (Oct 13, 2022)1681652

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CDK2AP1protein_codingprotein_codingENST00000261692 411354
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.4480.526125742021257440.00000795
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.423567.90.5150.00000456723
Missense in Polyphen720.3890.34333244
Synonymous0.1682728.10.9600.00000210226
Loss of Function1.7915.530.1812.36e-769

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00001760.0000176
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: specific inhibitor of the cell-cycle kinase CDK2. {ECO:0000250}.;

Recessive Scores

pRec
0.156

Intolerance Scores

loftool
0.180
rvis_EVS
-0.03
rvis_percentile_EVS
51.04

Haploinsufficiency Scores

pHI
0.697
hipred
Y
hipred_score
0.688
ghis
0.613

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.923

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Cdk2ap1
Phenotype
craniofacial phenotype; cellular phenotype; growth/size/body region phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);

Gene ontology

Biological process
positive regulation of protein phosphorylation;DNA-dependent DNA replication;cell cycle
Cellular component
nucleus;nucleoplasm;cytosol;perinuclear region of cytoplasm
Molecular function
protein binding;DNA polymerase binding